Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-004 · synthetic case IRON-FX-11
Anemia in chronic kidney disease
Hb 10.2, ferritin 140 and TSAT 17 in CKD.
Purpose: Hb 10.2, ferritin 140 and TSAT 17 in CKD.
Inputs the engine received
Iron studies
- Ferritin
- 140 ng/mL
- Serum iron
- 41 µg/dL
- TIBC
- 241 µg/dL
CBC
- Hemoglobin
- 10.2 g/dL
- MCV
- 90 fL
Patient
- Age
- 62 years
- Sex
- Male
Conditions and risk groups
- Chronic kidney disease
- Yes
What the engine reports
Detected clinical pattern
Anemia Without an Iron-Deficiency Criterion
Hemoglobin is below threshold and no iron-deficiency criterion is met with the values entered. Other causes of anemia remain open.
- Anemia: Anemia (Hb 10.2 g/dL)
Calculations
- Transferrin saturation
- 17%
Serum iron ÷ TIBC × 100.
Recommended next steps
For physician consideration. Urgent review always comes first.
- 1Assess ferritin and transferrin saturation before an ESA is considered; KDIGO 2012 suggests an iron trial when TSAT ≤30% and ferritin ≤500 ng/mL.Decision belongs to the treating physician or nephrologist.
Evidence and rule trace · 3 rules
ID-AN-01Anemia present by WHO thresholds
Inputs: hemoglobin 10.2 g/dL (<13)
Anemia by WHO hemoglobin thresholds.
ID-CKD-01Chronic kidney disease with anemia
Inputs: CKD · hemoglobin 10.2 g/dL
Iron indices should be assessed before an erythropoiesis-stimulating agent is considered.
Evidence
- EV-WHO-HB-2011 · World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: WHO; 2011.
- EV-KDIGO-ANEMIA-2012 · KDIGO Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.
- EV-MENTZER-1973 · Mentzer WC Jr. Differentiation of iron deficiency from thalassaemia trait. Lancet. 1973;1(7808):882.
Physician adjudication required. Clinical decision support for physician review. This output identifies laboratory patterns and safety considerations. It does not diagnose, find a cause, or select an iron product, dose or route. Physician adjudication is required.
Change the values
The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.
Stage of iron deficiency
○ 1 · Stores depleted
Low ferritin, normal CBC
○ 2 · Iron-deficient erythropoiesis
Low TSAT or reticulocyte Hb, Hb still normal
○ 3 · Anemia
Hemoglobin below the WHO threshold
No stage is assigned for the values entered.
Against typical reference intervals
Iron studiesDrag or type
- <15 depleted
- 15–29 low
- 30–44 borderline
- 45–299
- 300–999 high
- >1000 very high
Calculated from iron ÷ TIBC when both are entered.
Above 5 mg/L the engine reads ferritin as inflammation-affected.
CBC
- <7 severe
- 7–11.9 anemia range
- 12–12.9 (men <13)
- ≥13
Patient
Symptoms and findings
Conditions and risk groups
Work-up and treatment context
More iron cases
IRON-FX-01
Classic iron-deficiency anemia in a premenopausal woman
A 34-year-old with heavy periods, Hb 9.8, MCV 72 and a ferritin of 6.
IRON-FX-02
Normal CBC, low ferritin, fatigue and hair loss
A 29-year-old with a normal CBC and a ferritin of 18.
IRON-FX-03
Iron-deficiency anemia in a man
A 61-year-old man with Hb 10.9, MCV 76 and a ferritin of 9.
IRON-FX-04
Iron-deficiency anemia after menopause
A 67-year-old woman, postmenopausal, Hb 10.6, ferritin 11.
IRON-FX-05
Rheumatoid arthritis: ferritin 85, TSAT 12
Hb 10.4 with a ferritin that looks normal and a CRP of 18.
IRON-FX-06
Inflammation with ferritin 48 and TSAT 9
Ferritin looks near normal but sits under the WHO inflammation cutoff of 70.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.